RLYB · Rallybio Corporation · Stock research

de# RLYB — Rallybio Corporation

Current Thesis

The material fact the last read underweighted: on 2026-05-04 Rallybio collected a $50.0M parent termination fee plus $0.4M of expense reimbursement after Candid Therapeutics walked from its 2026-03-01 merger agreement to take a UCB deal (Candid terminated 2026-05-03). That cash landed after the 3/31/26 balance-sheet date, so every net-cash figure lifted from the Candid-era S-4 — the ~$35.8M as of 2026-04-15, the ~$37.5M carried in earlier deal math — is pre-windfall and understates the distributable pile by roughly $50M.

Rerun the arithmetic. Q1 close carried $41.3M cash + $5.5M marketable securities = $46.8M; add $50.4M and the gross sits near $97M against 5.30M shares outstanding, or ~$18.3/share before burn. Against a $16.42 quote (2026-07-17, +2.88%) and an $87.0M market cap, a buyer is paying at or near the cash distribution alone and receiving the CVR and the 2.8% stub for close to nothing. That is a sum-of-parts trade with a defined event calendar — no accelerating narrative, no momentum leg, and a Q4 2026 close that locks capital for roughly a quarter and a half.

Bullish and bearish views on Rallybio Corporation

The model's bull view on Rallybio Corporation (RLYB), in brief: 2026-05-04: $50.0M termination fee + $0.4M expenses received. The bear view: The net-cash figure is inferred, not disclosed. Both cases follow in full.

Bull Case

• 2026-05-04: $50.0M termination fee + $0.4M expenses received. A busted deal paid Rallybio more than half its then-market cap, and the cash flows to legacy holders because the merger agreement has the company "distribute substantially all of its pre-closing net cash to its pre-closing stockholders."
• 2026-03-31 balance sheet: $41.3M cash + $5.5M securities. Stacked with the fee, gross pre-burn cash of ~$97M / 5.30M shares ≈ $18.3 per share, against a $16.42 tape. Trailing-twelve-month net loss of only $7.82M shows a cost base already gutted through the 2025 strategic review, so quarterly burn between here and close is small relative to the pile.
• Free CVR per share: entitles holders to net proceeds from the Recursion membership-interest purchase covering the REV102 program plus disposition of other legacy assets, with a one-year post-closing disposition window under the CVR construct. Costs nothing at these prices; pays zero if nothing sells.
• Blue-chip $215M PIPE, oversubscribed: Blackstone, accounts advised by T. Rowe Price, Vivo Capital, OrbiMed, Affinity Asset Advisors and ADAR1 Capital Management. Financing fall-through risk is low, which is the single largest determinant of whether the 2.8% stub converts into a listed AVZO share at all.
• Reverse break protection: Avenzo owes Rallybio $20.0M on certain terminations ($8.0M after the End Date) plus up to $750K of expenses, against only $600K flowing the other way. Asymmetric, and this management has already banked one break fee.
• 2026-06-01 ASCO: AVZO-021, a selective CDK2 inhibitor, produced 5.3-month median PFS in heavily-pretreated HR+/HER2− breast cancer (median four prior lines) with low-incidence GI and heme tolerability. The $215M funds four programs into late 2028 across multiple Phase 1 readouts and several Phase 2 starts.

Bear Case

• The net-cash figure is inferred, not disclosed. $97M gross is arithmetic on a 3/31 balance sheet plus a dated receipt. Deduct roughly three quarters of shell opex and Avenzo transaction and legal costs and a $75–85M distributable range is the realistic band, i.e. $14–16 per share. At $16.42 the discount is thin to nonexistent at the low end of that band.
• Legacy holders own 2.8% of the future. Implied valuations of $15M for Rallybio and $300M for Avenzo drive the exchange ratio; the $215M financing takes 40.6%, implying ~$530M pro-forma equity. The stub is worth ~$2.83/share at deal marks and small-cap reverse-merger stubs routinely settle below PIPE price on the first free-trading tape.
• The 2.8% is struck assuming ~$0 net cash at close because the cash is distributed first. Any leakage — higher deal costs, a larger retained reserve, an escrow against legacy liabilities — comes straight out of the distribution, not out of the stub.
• A position of any size cannot be exited into a deal-break print.
• No proxy record date or special-meeting date is public as of 2026-07-19. The merger agreement requires the Rallybio meeting no later than 45 calendar days after the registration statement is declared effective, so the calendar is constrained but not yet dated.
• The move already happened. From a 52-week low of $3.20 to $16.42 is a five-bagger driven by two discrete events, both banked.

Setup & Price Structure

Price $16.42 on 2026-07-17 (+2.88% that session), inside a 52-week range of $3.20–$17.57 and sitting in the top ~6% of it. Market cap $87.0M on 5.30M shares — share count reflects the 1-for-8 reverse split effective 2026-02-06, executed for Nasdaq listing compliance while the company was winding down, before either deal existed.

Seven weeks after the 2026-06-01 announcement the stock has not round-tripped; it has ground from ~$15.71 (2026-06-25) to ~$16.06 (2026-06-29) to $16.42, a slow upward drift on thin volume rather than a momentum impulse. That is what an arb book accumulating toward a cash floor looks like. Beta of -0.89 confirms the obvious: this ticker does not trade with the tape.

The structural read is a compressed range beneath the $17.57 high with a soft floor wherever the eventual distribution prints. There is no moving-average setup worth trading here and no volume signature to follow — the chart is a valuation band, and the band's width is the uncertainty in the net-cash number.

Catalyst Calendar (next 30 days)

• Undated, legacy-asset dispositions: any announced sale of REV102-related interests or other legacy assets marks the CVR before close rather than after.
• Q4 2026 (no fixed date), transaction close: conditioned on both stockholder votes, S-4 effectiveness, Nasdaq listing approval and completion of the $215M financing. Falls outside this window.

Elapsed catalysts

• ~2026-08-06 (est.), Q2 2026 results: the decisive item. The first balance sheet to carry the $50.4M receipt and the first hard read on burn since the Candid break. This print converts the $75–85M distributable estimate into a number. (passed 3d ago)
• Ongoing, S-4 / proxy-prospectus effectiveness: a registration statement covering the Avenzo transaction is on file. Effectiveness triggers the 45-day clock to the Rallybio special meeting and should disclose the assumed net cash, the final reverse-split ratio and the record date. No effectiveness date is public as of 2026-07-19. (passed 21d ago)

What Would Change Our Mind

A weekly close below $13 breaks the read — that level sits under any plausible distribution floor consistent with the 2026-05-04 receipt and would mean the market is pricing either a deal break or a distribution far smaller than the balance sheet implies. Second condition: if the ~2026-08-06 Q2 print shows pre-closing net cash under roughly $70M, the margin of safety is gone at $16.42 and the name reverts to a fully-valued stub-plus-lottery-ticket.

On the other side, a disclosed net cash figure above ~$85M with a dated special meeting turns this from a fair-value hold into a genuine discount, and would justify sizing up rather than probing. A second termination — Avenzo walking and paying the $20.0M fee — is not a disaster case here; it returns the vehicle to a cash shell holding more cash per share than it did in March.

Correlation Notes

Beta of -0.89 makes this a poor XBI or SPY proxy; the price is a function of deal-completion odds and a cash number, not biotech risk appetite. It correlates with the reverse-merger-shell cohort — busted clinical-stage names re-rating off strategic reviews — and with financing conditions for private oncology, since a PIPE that cannot fund is the main path to a broken deal. It does not correlate with the CDK2/CDK4 competitive landscape in any tradeable way today: that exposure only arrives with the 2.8% stub after close.

The oncology story is an AVZO story. Anyone underwriting AVZO-021, AVZO-023, the AVZO-1418 EGFR/HER3 ADC or the AVZO-103 Nectin4/TROP2 ADC should wait for the post-close listing and a fresh setup rather than buying 2.8% of it wrapped inside a cash-distribution vehicle. This dossier should re-tag to AVZO once the merger closes.